ADHD currently stands as one of the most common neurobehavioral disorders in the United States, and is characterized by marked difficulty paying attention, impulsive behavior and, in some cases, being overly active. In a 2009 report from the Centers of Disease Control and Prevention, approximately one in 10 children (9.5 percent) ages 4 to 17 in the United States have received a diagnosis of ADHD. The condition often continues into adulthood, and roughly 4 percent of Americans are believed to be affected with adult ADHD.

 

In a report released by GlobalData in October 2011, “Attention Deficit Hyperactivity Disorder (ADHD) Therapeutic: Pipeline Assessment and Market Forecasts to 2018,” the firm noted that the global ADHD therapeutics market had a value of approximately $3.8 billion in 2010, and is expected to grow at a compound annual growth rate of 8 percent over the next eight years, reaching roughly $7.1 billion by 2018.

 

The transaction is expected to close in the fourth quarter of this year, and is subject to customary closing conditions, including regulatory approval in the United States. No details were provided as to Pfizer’s plans for NextWave’s facilities or employees following the acquisition.

 

Pfizer brought on Jefferies & Company Inc. as its financial advisor for the transaction, and Pfizer Legal Alliance firms Kaye Scholer LLP and Ropes & Gray LLP were brought on as legal counsel. NextWave brought on Aquilo Partners LP as its financial advisor, while Cooley LLP served as the company’s legal advisor.